Buy Eliquis (Apixaban) Online at Lowest Price

Eliquis (apixaban), is a groundbreaking anticoagulant medication primarily utilized in the prevention and treatment of serious blood clot-related conditions. Developed through advanced pharmaceutical research, Eliquis offers a significant therapeutic option for patients at risk of stroke and systemic embolism, particularly those diagnosed with non-valvular atrial fibrillation. This condition, characterized by an irregular and often rapid heart rate, increases the risk of clot formation in the heart, which can travel to the brain, causing a stroke.

Beyond its application in atrial fibrillation, Eliquis is also indicated for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Deep vein thrombosis is a condition where blood clots form in the deep veins of the body, usually in the legs, which can lead to pulmonary embolism if the clot travels to the lungs. Eliquis effectively reduces the risk of these events by inhibiting specific pathways involved in blood clot formation.

Why Do You Need Eliquis?

Eliquis is prescribed for several critical conditions that pose significant health risks. The primary use of Eliquis is in patients with atrial fibrillation not caused by a heart valve problem, a common and serious heart rhythm abnormality that escalates the risk of stroke. In this context, Eliquis acts as a preventive measure to lower the chance of blood clots forming in the heart and subsequently traveling to the brain, which could lead to stroke, a leading cause of death and disability worldwide.

Moreover, Eliquis is a vital treatment option for the management and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Individuals undergoing certain types of surgeries, such as hip or knee replacement surgery, are at an increased risk of developing DVT, where blood clots form in the veins of the leg. Without effective management, these clots can dislodge and travel to the lungs, causing PE, a potentially fatal condition. Eliquis provides a means to reduce this risk significantly.

For patients who have previously experienced DVT or PE, Eliquis is also used to prevent recurrence. Recurrent events are common and can have serious consequences, making effective, ongoing treatment essential for those at risk. Eliquis offers a favorable balance of efficacy and safety for these patients, providing effective clot prevention with a lower risk of bleeding compared to older anticoagulants.

Eliquis is needed because it represents a modern approach to anticoagulation, offering patients more stable blood thinning without the need for frequent blood tests to monitor therapeutic levels. This ease of use, combined with its effective prevention of thrombotic events, improves patient compliance and overall treatment outcomes.

The role of Eliquis extends beyond merely preventing clot formation; it is a part of a broader therapeutic strategy aimed at improving patient outcomes in conditions where thrombosis is a primary concern. By reducing the incidence of stroke and systemic embolism in atrial fibrillation patients, and preventing and treating DVT and PE, Eliquis plays a crucial role in cardiovascular health management.

Eliquis Mechanism of Action

Eliquis operates through a specific and targeted mechanism of action, distinguishing it from traditional anticoagulants. It directly inhibits Factor Xa, a critical enzyme in the coagulation cascade that catalyzes the conversion of prothrombin to thrombin. By inhibiting this enzyme, Eliquis effectively reduces thrombin generation and, consequently, blood clot formation. This targeted action allows for precise control over the anticoagulation process, significantly lowering the risk of stroke in patients with non-valvular atrial fibrillation and preventing the formation and recurrence of DVT and PE.

The advantage of Eliquis’s mechanism of action lies in its ability to provide anticoagulation without the need for the coagulation monitoring that is necessary with warfarin, another anticoagulant. Additionally, the direct inhibition of Factor Xa by Eliquis is associated with a lower risk of major bleeding events, a significant concern with anticoagulant therapy.

Another important aspect of Eliquis's mechanism is its minimal interaction with food and other medications, a common issue with older anticoagulants. This allows for more consistent and predictable anticoagulation management, with fewer dietary restrictions and reduced need for dose adjustments.

Eliquis's mechanism of action also provides a rapid onset and offset of anticoagulation, offering flexibility and convenience for patients who may need to interrupt their anticoagulation therapy for surgical procedures or other medical interventions. The predictable pharmacokinetics and pharmacodynamics of Eliquis facilitate easier management of these clinical situations.

In What Forms and Dosages Eliquis Is Available?

Eliquis (apixaban) is available in tablet form, designed for oral administration, making it convenient for patients to take. The tablets come in two strengths: 2.5 mg and 5 mg, allowing for flexibility in dosing based on patient-specific factors such as kidney function, body weight, and concomitant medications.

The availability of Eliquis in tablet form and at these specific dosages allows for straightforward, oral administration without the need for injections or IV administration, a significant advantage in terms of patient comfort and convenience.

How Long Does It Take to See Results with Eliquis?

The effects of Eliquis, while not immediately perceptible to patients, begin to manifest within hours after the first dose. Its primary function is to prevent the formation of blood clots, a process that doesn't produce noticeable sensations. Clinical studies indicate that Eliquis reaches its peak concentration in the blood approximately 3 to 4 hours after ingestion, starting to exert its anticoagulant effects rapidly. However, the clinical outcomes, such as the prevention of stroke or systemic embolism in patients with atrial fibrillation, or the treatment and prevention of DVT and PE, are measured over time and with regular medical follow-up.

For patients taking Eliquis for atrial fibrillation, the protective effects against stroke and systemic embolism are ongoing and are a result of consistent use as prescribed. Similarly, in the context of DVT and PE treatment, the initial high-dose phase (10 mg twice daily for 7 days) quickly reduces the risk of clot extension and embolization. Following this phase, the maintenance dose (5 mg twice daily) helps prevent new clot formation.

The timeframe for visible outcomes can vary based on individual risk factors and the condition being treated. For example, in the prevention of recurrent DVT and PE, patients might be transitioned to a lower dose (2.5 mg twice daily) after 6 months, based on their risk of recurrence and bleeding.

Accessibility and Cost of Treatment

The cost for Eliquis (apixaban) can vary. For a supply of 60 tablets of Eliquis 5 mg, the cost is around $635, depending on the pharmacy you visit. It's important to note that these prices are for cash-paying customers and might not apply if you have insurance. For further savings, Eliquis offers may include coupons, rebates, savings cards, trial offers, or free samples. One notable program is the Eliquis Co-pay Card, where eligible patients may pay as little as $10 per 30-day supply for up to 24 months, with a maximum annual savings of $6400. Additionally, there's a free 30-day trial offer available for eligible patients, limited to one use per patient per lifetime, which could significantly reduce the cost for new patients.

What About the Side Effects?

The most significant risk associated with Eliquis is bleeding, including serious events such as gastrointestinal bleeding or intracranial hemorrhage.

Less serious side effects may include nausea, anemia, and skin rash.

Despite the risk of side effects, many patients take Eliquis without significant issues, benefiting from its protective effects against stroke and thromboembolism.

How to Take Eliquis?

Eliquis is taken orally, with or without food, usually twice a day. It's important to take Eliquis at the same times each day to maintain steady drug levels in the blood. Consistency in dosing helps optimize the medication's efficacy and safety.

Nonvalvular Atrial Fibrillation: For patients with nonvalvular atrial fibrillation, the primary goal of Eliquis is to reduce the risk of stroke and systemic embolism. The standard dosage is 5 mg taken orally twice a day. However, for patients who meet two of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, the recommended dose is reduced to 2.5 mg twice a day.

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Treatment: For the treatment of DVT and PE, the initial dosage is typically 10 mg taken orally twice a day for the first 7 days, followed by 5 mg taken twice a day. This regimen aims to quickly reduce the risk of clot formation and ensure effective management of the conditions.

Prevention of Recurrent DVT and PE: After completing initial treatment for DVT or PE, patients may be prescribed Eliquis to prevent the recurrence of these conditions. The recommended dose for this purpose is 2.5 mg taken orally twice a day, following at least 6 months of treatment with a higher dose for the initial DVT or PE.

Prevention of DVT Following Hip or Knee Replacement Surgery: Eliquis is also used to prevent DVT, which can lead to PE, following hip or knee replacement surgery. The recommended dosage for this indication is 2.5 mg taken orally twice a day. The first dose should be taken 12 to 24 hours after surgery, and the treatment duration is usually 35 days for hip replacement surgery and 12 days for knee replacement surgery.

Does Eliquis Improve Quality of Life?

The Eliquis role in preventing serious health events like stroke and thromboembolism can indirectly contribute to a better quality of life. By reducing the risk of such conditions, patients may experience less anxiety and stress about their health, potentially improving overall well-being.

The fear of stroke, especially among patients with atrial fibrillation, can significantly impact mood and quality of life. Effective stroke prevention with Eliquis can alleviate these concerns, allowing patients to feel more secure in their health management strategy.

Additionally, the simplified dosing and reduced need for routine blood monitoring compared to traditional anticoagulants like warfarin can lessen the treatment burden on patients, further enhancing quality of life.

Patients who have experienced DVT or PE may also find that successful prevention of recurrence with Eliquis allows them to engage more fully in daily activities and exercise, contributing to improved physical health and mood.

Overall, while the primary goal of Eliquis therapy is to prevent thromboembolic events, its use can have a broader impact on patients' lives, potentially improving quality of life through enhanced health security and treatment convenience.